AZN Relative Valuation
AZN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AZN is overvalued; if below, it's undervalued.
Historical Valuation
AstraZeneca PLC (AZN) is now in the Undervalued zone, suggesting that its current forward PS ratio of 4.66 is considered Undervalued compared with the five-year average of 16.93. The fair price of AstraZeneca PLC (AZN) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 89.97 USD , AstraZeneca PLC is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：89.97
Fair
Undervalued
0.00
PE
1Y
3Y
5Y
Trailing
Forward
14.22
EV/EBITDA
AstraZeneca PLC. (AZN) has a current EV/EBITDA of 14.22. The 5-year average EV/EBITDA is 13.90. The thresholds are as follows: Strongly Undervalued below 11.38, Undervalued between 11.38 and 12.64, Fairly Valued between 15.16 and 12.64, Overvalued between 15.16 and 16.43, and Strongly Overvalued above 16.43. The current Forward EV/EBITDA of 14.22 falls within the Historic Trend Line -Fairly Valued range.
15.02
EV/EBIT
AstraZeneca PLC. (AZN) has a current EV/EBIT of 15.02. The 5-year average EV/EBIT is 14.65. The thresholds are as follows: Strongly Undervalued below 12.17, Undervalued between 12.17 and 13.41, Fairly Valued between 15.90 and 13.41, Overvalued between 15.90 and 17.14, and Strongly Overvalued above 17.14. The current Forward EV/EBIT of 15.02 falls within the Historic Trend Line -Fairly Valued range.
4.61
PS
AstraZeneca PLC. (AZN) has a current PS of 4.61. The 5-year average PS is 4.22. The thresholds are as follows: Strongly Undervalued below 3.44, Undervalued between 3.44 and 3.83, Fairly Valued between 4.60 and 3.83, Overvalued between 4.60 and 4.99, and Strongly Overvalued above 4.99. The current Forward PS of 4.61 falls within the Overvalued range.
16.72
P/OCF
AstraZeneca PLC. (AZN) has a current P/OCF of 16.72. The 5-year average P/OCF is 18.09. The thresholds are as follows: Strongly Undervalued below 14.08, Undervalued between 14.08 and 16.09, Fairly Valued between 20.10 and 16.09, Overvalued between 20.10 and 22.11, and Strongly Overvalued above 22.11. The current Forward P/OCF of 16.72 falls within the Historic Trend Line -Fairly Valued range.
24.68
P/FCF
AstraZeneca PLC. (AZN) has a current P/FCF of 24.68. The 5-year average P/FCF is 24.67. The thresholds are as follows: Strongly Undervalued below 17.88, Undervalued between 17.88 and 21.27, Fairly Valued between 28.06 and 21.27, Overvalued between 28.06 and 31.46, and Strongly Overvalued above 31.46. The current Forward P/FCF of 24.68 falls within the Historic Trend Line -Fairly Valued range.
AstraZeneca PLC (AZN) has a current Price-to-Book (P/B) ratio of 3.07. Compared to its 3-year average P/B ratio of 5.46 , the current P/B ratio is approximately -43.79% higher. Relative to its 5-year average P/B ratio of 6.04, the current P/B ratio is about -49.16% higher. AstraZeneca PLC (AZN) has a Forward Free Cash Flow (FCF) yield of approximately 4.43%. Compared to its 3-year average FCF yield of 4.30%, the current FCF yield is approximately 3.11% lower. Relative to its 5-year average FCF yield of 3.86% , the current FCF yield is about 14.94% lower.
3.04
P/B
Median3y
5.46
Median5y
6.04
4.47
FCF Yield
Median3y
4.30
Median5y
3.86
Competitors Valuation Multiple
The average P/S ratio for AZN's competitors is 4.66, providing a benchmark for relative valuation. AstraZeneca PLC Corp (AZN) exhibits a P/S ratio of 4.61, which is -0.88% above the industry average. Given its robust revenue growth of 11.99%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of AZN increased by 37.41% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 10.56 to 16.69.
The secondary factor is the Revenue Growth, contributed 11.99%to the performance.
Overall, the performance of AZN in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is AstraZeneca PLC (AZN) currently overvalued or undervalued?
What is AstraZeneca PLC (AZN) fair value?
How does AZN's valuation metrics compare to the industry average?
What is the current P/B ratio for AstraZeneca PLC (AZN) as of Dec 05 2025?
What is the current FCF Yield for AstraZeneca PLC (AZN) as of Dec 05 2025?
What is the current Forward P/E ratio for AstraZeneca PLC (AZN) as of Dec 05 2025?